SoFi stock falls after announcing $1.5B public offering of common stock
Nektar Therapeutics (NASDAQ:NKTR) reported Friday that Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025. The company stated that Wilson’s departure is not the result of any disagreement with Nektar regarding its operations, policies, or practices.
Elizabeth Zhang, currently Vice President, Legal and Corporate Counsel, will assume Wilson’s responsibilities. Zhang joined Nektar in 2021 and previously held positions at law firms Cravath, Swaine & Moore LLP in New York City and Gibson, Dunn & Crutcher LLP in San Francisco. She holds a Bachelor of Arts in Neurobiology from Harvard College, a Master of Science in Neuroscience from the University of Oxford, and a Juris Doctor from Harvard Law School.
The information is based on a press release statement included in Nektar’s filing with the Securities and Exchange Commission.
In other recent news, Nektar Therapeutics reported a net loss of $35.5 million, or $1.87 per share, for the third quarter of 2025. Despite this, the company maintains a strong financial position with $270.2 million in cash and investments and no debt. Additionally, Nektar presented promising data from its Phase 2b REZOLVE-AD study, showing significant improvements in asthma symptoms for patients with atopic dermatitis using its experimental drug, rezpegaldesleukin. This data was shared at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. Oppenheimer has maintained its Outperform rating on Nektar Therapeutics, emphasizing the positive findings from the study. In other developments, Terra Innovatum Global announced the resignation of Martha Crawford from its board of directors for personal reasons. The company has begun searching for a replacement and appointed Katherine Williams to its Audit Committee. These updates reflect ongoing strategic and operational changes within both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.